Keuangan Merck & Co., Inc. (MRK)
NYSE · Healthcare · Drug Manufacturers - General · Karyawan: 74.000 · CEO: Robert Davis
- Harga
- $149,52 +2,18%
- Kapitalisasi pasar
- $369 M
- Nilai perusahaan
- $416 M
- Laporan terakhir
- Q3 '26 diajukan 2026-09-30
- Laporan berikutnya
- 2027-02-02 Estimasi EPS: $1,79
Pendapatan (TTM)$67,3 M+4,8% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)16,2%-22,5 poin vs tahun laluLaba operasional: $10,9 M
Laba bersih (TTM)$2,45 M-87,1% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)–– vs tahun laluCapex: –
EPS dilusian (TTM)$0,97-87,2% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$46,8 M-74,6% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $369 M EV $416 M
- Pendapatan
- $67,3 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +3% Konsensus FY2026
- Margin laba
- 3,6% Laba bersih / pendapatan, TTM
- P/E
- 152,6× Forward 54,4× (FY2026)
- P/S
- 5,5× Harga / penjualan, TTM
- EV / EBITDA
- 31,9× TTM
- Arus kas bebas
- – 12 bulan terakhir
- Laba bersih
- $2,45 M 12 bulan terakhir
- Estimasi pendapatan
- $67,1 M Konsensus FY2026
- Laba
- 2027-02-02 Estimasi pendapatan: $16,4 M
- Dividen
- $3,40 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-29): pendapatan melampaui 4,4%, EPS melampaui 19,1%Pendapatan $18,1 M vs $17,3 M yang diharapkan (+4,4%); EPS $2,49 vs $2,09 (+19,1%).
- Pertumbuhan pendapatan stabil: 5,2% yoyPendapatan Q3 '26: $18,1 M, rata-rata empat kuartal sebelumnya: 4,3%.
- Margin operasional 16,2% (TTM), dibanding tahun lalu: -22,5 poinLaba operasional tumbuh -56,1%, pendapatan tumbuh 4,8%.
- 129,5% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $4,76 M vs laba operasional $10,9 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Jumlah saham dilusian turun dalam setahun: 0,8%Saham dilusian pada Q3 '26: 2,48 M, setahun sebelumnya: 2,5 M.
- Utang neto: $46,8 MKas + investasi jangka pendek: $7,14 M, utang termasuk sewa: $53,9 M; tahun lalu utang neto: $26,8 M.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $18,1 M | $17,2 M | +5,2% |
| Margin kotor | 81,4% | 75,6% | +5,9 poin |
| Laba operasional | $7,33 M | $7,46 M | -1,7% |
| Margin operasional | 40,6% | 43,4% | -2,9 poin |
| Laba bersih | $5,07 M | $5,79 M | -12,4% |
| EPS dilusian | $2,04 | $2,32 | -12,1% |
| Arus kas operasional | – | $7,82 M | – |
| Capex | – | $987 jt | – |
| Arus kas bebas | – | $6,84 M | – |
| R&D | $4,53 M | $3,55 M | +27,6% |
| Kompensasi berbasis saham | – | $204 jt | – |
Dilaporkan vs konsensus
2026-10-29| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $18,1 M | $17,3 M | +4,4% |
| EPS (basis konsensus) | $2,49 | $2,09 | +19,1% |
Dari laporan 2026-10-29 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Pharmaceutical segment | $14,8 M | +5,1% | 88,9% | $59,6 M | +5,1% | |
| Animal Health segment | $1,78 M | +7,8% | 10,7% | $6,69 M | +9,3% | |
| Other Segments | $72 jt | -34,5% | 0,4% | $320 jt | -61,2% |
Pendapatan per wilayah
porsi dari total| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $9,37 M | +6,0% | 56,4% | $37,7 M | +9,9% | |
| EMEA | $3,92 M | +7,1% | 23,6% | $15,3 M | +8,5% | |
| CHINA | $408 jt | -8,5% | 2,5% | $1,59 M | -48,0% | |
| JAPAN | $577 jt | -7,8% | 3,5% | $2,55 M | -16,9% | |
| Latin America | $875 jt | +1,9% | 5,3% | $3,51 M | +1,5% | |
| Asia Pacific | $820 jt | +4,5% | 4,9% | $3,07 M | +0,2% | |
| International | $640 jt | +7,6% | 3,9% | $2,9 M | +10,6% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas bebas
- –
- Dikembalikan ke pemegang saham / FCF
- –
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 152,6× | 168,4× | 14,4× – 778,7× |
| EV / EBITDA | 31,9× | 18,4× | 10,6× – 44,5× |
| EV / Penjualan | 6,2× | 4,7× | 4,3× – 5,1× |
| Harga / FCF | 23,0× | 21,0× | 13,9× – 30,4× |
| Harga / Nilai buku | 8,8× | 5,8× | 5,0× – 7,4× |
| Imbal hasil FCF | 4,4% | 5,1% | 3,3% – 7,2% |
| Imbal hasil modal yang diinvestasikan | 5,4% | 14,1% | 0,7% – 19,0% |
| Imbal hasil ekuitas | 5,1% | 27,7% | 1,0% – 37,0% |
Analis
Target konsensus $159,95 (+7,0%)
rentang $105,00 – $180,00 · peringkat Buy
Beli kuat0
Beli26
Tahan11
Jual1
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $67,1 M | +3,4% | $2,75 | -62,3% | 54,4× | 13 |
| FY2027 | $69,5 M | +3,6% | $9,08 | +230,4% | 16,5× | 12 |
| FY2028 | $73,7 M | +5,9% | $9,99 | +10,0% | 15,0× | 7 |
| FY2029 | $74,1 M | +0,6% | $9,89 | -0,9% | 15,1× | 2 |
| FY2030 | $74,6 M | +0,7% | $9,78 | -1,2% | 15,3× | 4 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 295 angka yang ditandai Merck & Co., Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $3,83 M | $3,89 M | -1,7% | $4,4 M | $4,08 M | +8,0% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $12,6 M | $11,8 M | +6,1% | $11,8 M | $10,3 M | +14,6% |
| Accounts Receivable, Allowance for Credit Loss, Current | $108 jt | $94 jt | +14,9% | $97 jt | $89 jt | +9,0% |
| Accounts Receivable, Sale | $1,6 M | -$100 jt | +1.700,0% | $1,6 M | $2,1 M | -23,8% |
| Accrual for Environmental Loss Contingencies | $42 jt2025-12-31 | $41 jt | +2,4% | $42 jt | $41 jt | +2,4% |
| Accrued Income Taxes, Current | $4,22 M | $4,16 M | +1,6% | $4,73 M | $3,91 M | +20,7% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $22,7 M | $20,3 M | +12,2% | $21,9 M | $19,2 M | +14,4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$3,94 M | -$5,42 M | +27,3% | -$4,29 M | -$4,95 M | +13,3% |
| Additional Paid in Capital, Common Stock | $45 M | $44,6 M | +0,7% | $45 M | $44,7 M | +0,7% |
| Advertising Expense | – | – | – | $2,3 M | $2,4 M | -4,2% |
| Amortization | $984 jt | $601 jt | +63,7% | $2,79 M | $2,4 M | +16,6% |
| Amortization of Intangible Assets | – | – | – | $2,8 M | $2,4 M | +16,7% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 | 19 jt | -100,0% | 11 jt | 6 jt | +83,3% |
| Assets | $130 M | $118 M | +10,4% | $137 M | $117 M | +16,9% |
| Assets, Current | $36,7 M | $37,1 M | -1,0% | $43,5 M | $38,8 M | +12,2% |
| Assets, Fair Value Disclosure | $2,14 M | – | – | $1,82 M | $2,19 M | -16,9% |
| Buildings and Improvements, Gross | $18 M2025-12-31 | $16,4 M | +9,9% | $18 M | $16,4 M | +9,9% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $02025-12-31 | -$12 jt | +100,0% | -$52 jt | -$10 jt | -420,0% |
| Business Combination, Contingent Consideration, Liability | $02025-12-31 | $193 jt | -100,0% | $0 | $193 jt | -100,0% |
| Cash and Cash Equivalents, at Carrying Value | $6,85 M | $8,01 M | -14,5% | $14,6 M | $13,2 M | +10,0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $6,89 M | $8,07 M | -14,6% | $14,7 M | $13,3 M | +10,3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $1,49 M | -$659 jt | +326,6% | $1,37 M | $6,41 M | -78,6% |
| Common Stock, Dividends, Per Share, Declared | $0,85 | $0,81 | +4,9% | $3,28 | $3,12 | +5,1% |
| Common Stock, Par or Stated Value Per Share | $0,50 | $0,50 | 0,0% | $0,50 | $0,50 | 0,0% |
| Common Stock, Shares Authorized | 6,5 M | 6,5 M | 0,0% | 6,5 M | 6,5 M | 0,0% |
| Common Stock, Shares, Issued | 3,58 M | 3,58 M | 0,0% | 3,58 M | 3,58 M | 0,0% |
| Common Stock, Value, Issued | $1,79 M | $1,79 M | 0,0% | $1,79 M | $1,79 M | 0,0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$1,22 M | $3,97 M | -130,6% | $18,9 M | $17,3 M | +9,1% |
| Construction in Progress, Gross | $9,17 M2025-12-31 | $7,98 M | +14,8% | $9,17 M | $7,98 M | +14,8% |
| Cost of Goods and Services Sold | $4,4 M | $3,56 M | +23,6% | $16,4 M | $15,2 M | +7,8% |
| Current Federal Tax Expense (Benefit) | – | – | – | $499 jt | $944 jt | -47,1% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $4,07 M | $3,12 M | +30,4% |
| Current Income Tax Expense (Benefit) | – | – | – | $4,48 M | $4,05 M | +10,4% |
| Current State and Local Tax Expense (Benefit) | – | – | – | -$96 jt | -$15 jt | -540,0% |
| Debt Instrument, Fair Value Disclosure | $49,9 M | $31,3 M | +59,4% | $45,6 M | $32,6 M | +39,9% |
| Debt Securities, Available-for-sale | $292 jt | $707 jt | -58,7% | $101 jt | $536 jt | -81,2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $0 | $0 | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $292 jt | $707 jt | -58,7% | $101 jt | $536 jt | -81,2% |
| Debt, Current | $2,83 M | $1,43 M | +97,0% | $2,59 M | $2,65 M | -2,3% |
| Debt, Long-term and Short-term, Combined Amount | $53,9 M | $35,4 M | +52,3% | $49,3 M | $37,1 M | +32,9% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$1,59 M | -$1,48 M | -7,5% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$83 jt | $212 jt | -139,2% |
| Deferred Income Tax Expense (Benefit) | -$544 jt | -$448 jt | -21,4% | -$1,67 M | -$1,25 M | -33,8% |
| Deferred Income Tax Liabilities, Net | $1,43 M | $1,43 M | +0,4% | $1,44 M | $1,39 M | +3,7% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$3 jt | $14 jt | -121,4% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $140 jt2025-12-31 | $71 jt | +97,2% | $140 jt | $71 jt | +97,2% |
| Deferred Tax Assets, Gross | $7,56 M2025-12-31 | $5,98 M | +26,4% | $7,56 M | $5,98 M | +26,4% |
| Deferred Tax Assets, in Process Research and Development | $4,13 M2025-12-31 | $3,06 M | +35,0% | $4,13 M | $3,06 M | +35,0% |
| Deferred Tax Assets, Inventory | $72 jt2025-12-31 | $84 jt | -14,3% | $72 jt | $84 jt | -14,3% |
| Deferred Tax Assets, Net | $1,17 M2025-12-31 | $2,21 M | -47,3% | $1,17 M | $2,21 M | -47,3% |
| Deferred Tax Assets, Net of Valuation Allowance | $6,73 M2025-12-31 | $5,27 M | +27,8% | $6,73 M | $5,27 M | +27,8% |
| Deferred Tax Assets, Operating Loss Carryforwards, Foreign | $384 jt2025-12-31 | $324 jt | +18,5% | $384 jt | $324 jt | +18,5% |
| Deferred Tax Assets, Other | $1,24 M2025-12-31 | $802 jt | +54,1% | $1,24 M | $802 jt | +54,1% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits | $117 jt2025-12-31 | $224 jt | -47,8% | $117 jt | $224 jt | -47,8% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation | $382 jt2025-12-31 | $400 jt | -4,5% | $382 jt | $400 jt | -4,5% |
| Deferred Tax Assets, Valuation Allowance | $824 jt2025-12-31 | $710 jt | +16,1% | $824 jt | $710 jt | +16,1% |
| Deferred Tax Liabilities, Gross | $5,57 M2025-12-31 | $3,06 M | +82,2% | $5,57 M | $3,06 M | +82,2% |
| Deferred Tax Liabilities, Intangible Assets | $3,27 M2025-12-31 | $978 jt | +234,6% | $3,27 M | $978 jt | +234,6% |
| Deferred Tax Liabilities, Inventory | $451 jt2025-12-31 | $413 jt | +9,2% | $451 jt | $413 jt | +9,2% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-01